Polymer-Linked Ligand Dimer Strategy
Take a ligand. Connect two copies via a PEG linker of variable length. Screen the resulting series against your target. The PLD with the best potency tells you both (a) the approximate spacing of two binding sites on your target and (b) the most potent agonist/antagonist in your series. No crystal structure required.
Construction: 8-thio-cGMP + bifunctional VS-PEG-VS → PLD at both ends. PEG MW 282–20,000 Da → rms length 15–123 Å. The PEG number directly translates to distance scanned.
How to interpret the results:
- Flat potency across all PLD lengths: no bivalent engagement, either the sites are too far apart or only one site exists
- Sharp peak at intermediate length: clean bivalent spanning, distance readable from rms length formula
- Broad peak: elastic PLD sampling multiple conformations, or protein flexibility
- Hill coefficient drop (e.g., 1.7 → 1.1): signature of simultaneous two-site occupancy replacing independent binding
Kramer & Karpen 1998 numbers:
- OLF CNG channel: optimal 2000PEG, rms 39 Å, 260-fold improvement, K₁/₂ = 12 nM vs 3.1 µM
- RET CNG channel: optimal 1200PEG, rms 30 Å — different from OLF despite conserved binding sites
- PKG: optimal 282PEG (shortest), rms 15 Å — intrasubunit sites closer than crystal structure suggested
- Overall maximum: up to 1000× potency enhancement
Confirming bivalent binding: add free competitor ligand during PLD dissociation. If PLD is bivalently bound, free competitor at high concentration accelerates off-rate (it competes with the tethered arm for the second site). Kramer & Karpen confirmed this: 1 mM free cGMP speeds up 3400PEG-cGMP₂ dissociation — direct proof.
For protein targets without known structure: this is exactly the right tool. You don’t need the crystal structure. You scan PLD lengths, find the peak, and you have: (1) the site-to-site distance, (2) the best ligand you’ll ever make from that monomer.
Practical limits: works best when both target sites bind the same ligand (homo-bivalent) or related ligands (hetero-bivalent). Requires target protein stability and a functional assay (electrophysiology, enzyme activity, SPR, ITC). The PEG linker is non-immunogenic, metabolically inert, and membrane-permeant for some constructs.
Connections
[source]Spanning binding sites on allosteric proteins with polymer-linked ligand dimers[source]Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors**[about]Polyvalent Binding and Avidity[about]Intrinsic Binding Energy and Connection Gibbs Energy[applies]STRC Research Portal[see-also]STRC Gene Therapy sphere